X

Trial Profile

Long term safety study of amifampridine phosphate in patients with Congenital Myasthenic Syndromes (CMS)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 13 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amifampridine (Primary)
Indications Myasthenia gravis
Focus Proof of concept; Therapeutic Use
Acronyms CMS002
Sponsors Catalyst Pharmaceuticals

Most Recent Events

04 Sep 2021 Status changed from completed to discontinued.
09 Aug 2017 According to a Catalyst Pharmaceuticals media release, data was presented at the 13th International Conference on Myasthenia Gravis and Related Disorders in May, 2017.
09 Aug 2017 Status changed from recruiting to completed, according to a Catalyst Pharmaceutical media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com